NASDAQ: OKUROnkure Therapeutics Inc Stock
$4.61-0.01 (-0.22%)
Updated Mar 14, 2025
OKUR Price
$4.61
Fair Value Price
N/A
Market Cap
$61.94M
52 Week Low
$1.25
52 Week High
$19.60
P/E
-0.3x
P/B
0.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$52.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$51M
Beta
0.67
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
OKUR Overview
Reneo Pharmaceuticals Incorporated develops therapies for patients with rare genetic mitochondrial diseases. REN001 is a selective peroxisome proliferator-activated receptor delta agonist in (1) Phase IIb clinical trials in patients with primary mitochondrial myopathies, and (2) Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals was incorporated in 2014 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OKUR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OKUR
Ranked#421 of 484
Ranked#421 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important OKUR news, forecast changes, insider trades & much more!
OKUR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OKUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OKUR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OKUR is good value based on its book value relative to its share price (0.6x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
OKUR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OKUR due diligence checks available for Premium users.
Valuation
OKUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
-118.09x
Market
3,446.57x
OKUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
4.68x
OKUR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OKUR's financial health
Profit margin
Revenue
$0.0
Net Income
-$35.2M
Profit Margin
0%
OKUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$114.9M
Liabilities
$11.1M
Debt to equity
0.11
OKUR's short-term assets ($113.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OKUR's short-term assets ($113.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OKUR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OKUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.0M
Investing
-$45.4M
Financing
$114.2M
OKUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OKUR vs Biotech Stocks
Onkure Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.